Major Rectal Cancer Treatment Breakthrough
A groundbreaking cancer trial at Sloan Kettering of a new drug, dostarlimab, has shown unprecedented results: the cancer disappeared in 100% of the trial participants.
A groundbreaking cancer trial at Sloan Kettering of a new drug, dostarlimab, has shown unprecedented results: the cancer disappeared in 100% of the trial participants.
Cancer of the uterus, also called endometrial cancer, is increasing so rapidly that it is expected to displace colorectal cancer by 2040 as the third most common cancer among women, and the fourth-leading cause of women’s cancer deaths.
The results of the trials were so impressive that research scientists received a standing ovation when they presented their data at an oncology conference in Chicago.
[vc_row][vc_column][vc_column_text]A total of 15 awards totaling more than $700K marks another record year of postdoctoral cancer research support Grants benefit researchers at Johns Hopkins School of Medicine, The Dana-Farber Cancer…
Read more
[vc_row][vc_column][vc_column_text] More than 46,000 cancers in America each year, or about 3 percent of cases, could be prevented by meeting physical activity guidelines. By Gretchen Reynolds, NY TimesNov. 17, 2021…
Read more
[vc_row][vc_column][vc_column_text] We very much appreciate all of our 2021 postdoctoral grantees, and their outstanding contributions to advance cancer research. NCC 2021-2022 Post Doctoral Grantees: Jiao Li, PhD., Dana-Farber Cancer…
Read more
There is some very good news on the prostate cancer front. According to an article in the New York Times on June 25, 2021, a new therapy for aggressive prostate…
Read more
The National Cancer Center is pleased to announce the recipients of its 2021-22 research grant awards, which support research fellows pursuing promising and innovative cancer research. This year’s class includes a total…
Read more
NY TIMES article on new advice from an influential panel will make more women and African-Americans eligible for CT scans, but some who need them most may not be able to afford them.
At the recommendation of Scientific Advisory Board member Dr. John Kirkwood, NCC has been funding post doctoral research in melanoma for over two decades. We commend Yale researchers for their new findings. Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery.
